NCT07867249Not yet recruiting
Efficacy and Safety of Cream Containing Fig Extract in Subacute and Chronic Eczematous Dermatitis Volunteers
Source: ClinicalTrials.gov · Last updated 9 Oct 2026
Brief summary (registry, in English)
This study aims to evaluate the efficacy and safety of a cream containing fig extract in volunteers with subacute and chronic eczematous dermatitis. The affected area of subacute and chronic eczematous dermatitis in each participant will be equally divided into two sections (left and right) using block randomization. One section (Area A) will receive the fig extract cream, while the other section (Area B) will receive a placebo cream as the control. All study assessments, including clinical assessments, skin parameter measurements, patient-reported outcomes, and adverse event assessments, will be performed at baseline and at 1, 2, and 3 weeks after treatment initiation.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 5 Oct 2026
- Start date
- Oct 2026
- Primary completion date
- May 2027
- Lead sponsor
- Chulalongkorn University
- NCT number
- NCT07867249
What you commit to
- Study type: Interventional
- Planned participants: 20
- From Oct 2026 to the primary completion date, May 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Used topical medications for itching or oral corticosteroids within 2 weeks
Other illness
- Allergic to fig extract
Other
- Have dermatitis on face, genital area, palms, or soles.
- Ppregnant or breastfeeding
- Participating in other clinical research studies
Who the study is looking for
- Male or female participants aged 18 years or older.
- Have subacute or chronic eczematous dermatitis greater than 6.25 cm²
- Have SCORAD Index score of less than 50, indicating mild to moderate dermatitis.
- Able to read and write.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.